Company / Working Capital
Trevi Therapeutics, Inc. Working Capital History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$98.9M
FY2024
5-year range
$25.2M / $109.2M
FY2020-FY2024
Trend
+21.0%
vs FY2023
Sector context
#194 of 213
Health Care
What the data says
Among 213 Health Care companies, Trevi Therapeutics, Inc. is in the bottom 9% for working capital. Working Capital has fluctuated over the past 7 years, ranging from $6M in FY2018 to $109M in FY2022.
Based on SEC 10-K filings.
$99M in FY2024 with a 5-year CAGR of +12.7%.
Declined from $109M to $99M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +57.7%
- 5-Year CAGR
- +12.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 213This company $98.9M Sector average $934.6M
▼
-89.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.7%, indicating consistent growth.
- In FY2024, working capital increased 21.0% year-over-year.
- Ranks #194 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $98.9M | +21.0% |
| FY2023 | $81.7M | -25.2% |
| FY2022 | $109.2M | +332.8% |
| FY2021 | $25.2M | -38.0% |
| FY2020 | $40.7M | -25.1% |
| FY2019 | $54.4M | +784.1% |
| FY2018 | $6.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026